The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in ...

Bayer has completed its rolling marketing application for prostate cancer drug darolutamide in the US, setting up possible approval later this year and a market clash with Pfizer/Astellas and ...

The German pharma developed darolutamide in partnership with Finland’s Orion Corporation, with the latter due a series of payments when the drug is filed in major markets. The ARAMIS trial ...

Bayer BAYRY announced that the FDA has accepted its supplemental new drug application (sNDA) for Nubeqa (darolutamide ... the industry’s growth of 4.8%. Image Source: Zacks Investment Research ...

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, which focused on Black patients with metastatic hormone-sensitive prostate cancer.